Morning Versus Evening Exercise for Adults With Overweight and Obesity (TIC-TOC)
Primary Purpose
Overweight and Obesity
Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
AM-EX
PM-EX
Sponsored by

About this trial
This is an interventional treatment trial for Overweight and Obesity focused on measuring exercise, physical activity, weight loss
Eligibility Criteria
Inclusion Criteria:
- Female or Male
- Age 18-55 years
- Body Mass Index 25-40 kg/m2
- Physically inactive: defined as self-reporting <150 minutes per week of physical activity at moderate intensity or greater on a regular basis over the past 3 months.
- No self-report of acute or chronic disease (cardiovascular disease (CVD), diabetes, gastrointestinal disorders and orthopedic problems in particular)
- No plans to relocate within the next 6 months
- No plans for extended travel (> 1weeks) within the next 6 months
- No nicotine use
- Live or work within 30 minutes of the AHWC (exceptions may be made at the discretion of the Study PI on a case by case basis for highly motivated subjects).
- Capable and willing to give informed consent, understand exclusion criteria, accept the randomized group assignment, and complete outcome measures.
- Own a smartphone and willing to download and use text messaging for meal intake and other related assessments.
- Have a primary care physician (or are willing to establish care with a primary care physician prior to study enrollment) to address medical issues which may arise during screening or study procedures/interventions.
For Females
- Not currently pregnant or lactating
- Not pregnant within the past 6 months
- Not planning to become pregnant in the next 6 months; sexually active women of childbearing potential may be enrolled if they have had a tubal ligation or use a reliable means of contraception
Exclusion Criteria:
- Diastolic blood pressure > 100 mm HG or systolic blood pressure > 160 mm HG.
- Resting heart rate >100
- Diabetes (fasting glucose ≥126 mg/dL or Hemoglobin A1C ≥6.5%)
- Undiagnosed hypo- or hyper-thyroidism (TSH outside of the normal range) or history of uncontrolled thyroid disorder. History of thyroid disease or current thyroid disease treated with a stable medication regimen for at least 6 months is acceptable.
- Hematocrit, white blood cell count or platelets significantly outside the normal reference range.
- Triglycerides > 400 mg/dL
- LDL cholesterol >200 mg/dL
- Abnormal resting electrocardiogram (ECG): serious arrhythmias, including multifocal PVC's, frequent PVC's (defined as 10 or more per min), ventricular tachycardia (defined as runs of 3 or more successive PVC's), or sustained atrial tachyarrhythmia; 2nd or 3rd degree A-V block, QTc interval > 480 msec or other significant conduction defects.
- Presence or history of any metabolic or chronic health problems which would affect appetite, food intake, energy metabolism, or ability to optimally participate in the exercise component including: CVD, peripheral vascular disease, cerebrovascular disease, significant cardiac arrhythmias or cardiac valve disease, diabetes, uncontrolled hyper- or hypothyroidism, uncontrolled hypertension, cancer (within the last 5 years, except skin cancer or other cancers considered cured with excellent prognosis), HIV infection, significant gastrointestinal disorders (described below), significant pulmonary disorders (described below), significant renal, musculoskeletal, neurologic, hematologic, or psychiatric disease.
- Significant gastrointestinal disorders including: chronic malabsorptive conditions, peptic ulcer disease, Crohn's disease, Ulcerative Colitis, chronic diarrhea, or active gallbladder disease.
- Significant pulmonary disorders including: chronic obstructive pulmonary disease (COPD), interstitial lung disease, cystic fibrosis, or uncontrolled asthma.
- Symptoms suggestive of CVD: chest pain, shortness of breath at rest or with mild exertion, syncope.
- Regular use of prescription or over-the-counter medications known to significantly impact appetite, weight, sleep, or energy metabolism (e.g. appetite suppressants, lithium, stimulants, anti-psychotics, tricyclic antidepressants)
- Regular use of systemic steroids (other than Oral Contraceptive Pills).
- Regular use of obesity pharmacotherapeutic agents within the last 6 months.
- Previous obesity treatment with surgery or weight loss device, except: (1) liposuction and/or abdominoplasty if performed > 1 year before screening, (2) lap banding if the band has been removed > 1 year before screening, (3) intragastric balloon if the balloon has been removed > 1 year before screening (4) duodenal-jejunal bypass sleeve, if the sleeve has been removed > 1 year before screening or 5) AspireAssist or other endoscopically placed weight loss device if the device has been removed > 1 year before screening.
- Current alcohol or substance abuse
- Irregular sleep/wake patterns that may hinder ability to consistently exercise at a certain time of day (e.g. night shift-work, swing shifts, etc)
- Currently dieting or planning to alter diet during the exercise intervention
- Nicotine use (past 6 months)
- History of clinically diagnosed eating disorders including anorexia nervosa, bulimia, binge eating disorder. Pattern of response on the QEWP-5 suggestive of possible binge eating disorder or bulimia will require further assessment by the Study MD to determine if it is appropriate for the subject to participate in the study.
- Current severe depression or history of severe depression within the previous year, based on DSM-IV-TR criteria for Major Depressive Episode. Score > 18 on BDI will require further assessment by the Study MD to determine if it is appropriate for the subject to participate in the study.
- History of other significant psychiatric illness (e.g. psychosis, schizophrenia, mania, bipolar disorder) which in the opinion of the Study MD would interfere with ability to adhere to dietary or exercise interventions.
- Currently participating in or planning to participate in any formal weight loss or physical activity programs or clinical trials.
- Weight loss >5% in past 3 months for any reason except post-partum weight loss, weight gain >% in past 3 months requires assessment by PI to determine reason for weight gain and if it is appropriate for the subject to participate in the study.
- Weight loss of >50 lbs in past 3 years for any reason except post-partum weight loss.
Sites / Locations
- University of Colorado Anschutz Medical Campus
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Experimental
Arm Label
AM-EX
PM-EX
Arm Description
Participants in this group will be prescribed morning aerobic exercise.
Participants in this group will be prescribed evening aerobic exercise.
Outcomes
Primary Outcome Measures
Feasibility of Recruitment (Number of contacts)
Feasibility of recruitment will be evaluated by the number of people who contact study staff expressing interest in the study
Feasibility of Recruitment (eligibility rate)
Feasibility of recruitment will be evaluated by calculating the number of volunteers who contact study staff to express interest in participation, the eligibility rate (number eligible divided by total volunteers)
Feasibility of Recruitment (enrollment rate)
Feasibility of recruitment will be evaluated by calculating the enrollment rate (number enrolled divided by the number of total volunteers)
Adherence to Exercise Intervention (session attendance)
Adherence will be calculated as (number of sessions attended/number of sessions prescribed)
Adherence to Exercise Intervention (kcal adherence)
Adherence will be calculated as (number of kcals prescribed/ number of kcals of exercise completed)
Secondary Outcome Measures
Weight Change (kg)
Body weight will be measured at baseline and weeks 4, 8, 12, and 15 using a digital scale accurate to ±0.1 kg
Physical Activity Change (min/d)
Physical activity will be measured using the ActivPAL v4
Meal Timing Change (clock time of first meal)
Meal timing will be assessed using digital photography paired with a date and time stamp (time of first meal)
Meal Timing Change (clock time of last meal)
Meal timing will be assessed using digital photography paired with a date and time stamp (time of last meal)
Sleep Timing Change (mid-point of sleep)
Mid-point of sleep will be measured using the Actiwatch 2 (starting sleep time + (sleep duration/2))
Full Information
NCT ID
NCT04262115
First Posted
February 6, 2020
Last Updated
October 8, 2021
Sponsor
University of Colorado, Denver
1. Study Identification
Unique Protocol Identification Number
NCT04262115
Brief Title
Morning Versus Evening Exercise for Adults With Overweight and Obesity
Acronym
TIC-TOC
Official Title
Feasibility and Acceptability of Morning Versus Evening Exercise for Adults With Overweight and Obesity: A Randomized Pilot Study
Study Type
Interventional
2. Study Status
Record Verification Date
October 2021
Overall Recruitment Status
Completed
Study Start Date
February 6, 2020 (Actual)
Primary Completion Date
July 1, 2021 (Actual)
Study Completion Date
July 1, 2021 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Colorado, Denver
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
5. Study Description
Brief Summary
The purpose of this pilot study is to determine the feasibility and acceptability of randomizing adults with overweight and obesity to an exercise intervention of either prescribed morning aerobic exercise (AM-EX) or prescribed evening aerobic exercise (PM-EX) progressing to 2000 kcal/wk.
Detailed Description
The purpose of this pilot study is to determine the feasibility and acceptability of randomizing adults with overweight and obesity to an exercise intervention of either prescribed morning aerobic exercise (AM-EX) or prescribed evening aerobic exercise (PM-EX) progressing to 2000 kcal/wk. Specifically, the purpose of this study is to assess recruitment, retention, and adherence to the exercise interventions.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Overweight and Obesity
Keywords
exercise, physical activity, weight loss
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Investigator
Allocation
Randomized
Enrollment
33 (Actual)
8. Arms, Groups, and Interventions
Arm Title
AM-EX
Arm Type
Experimental
Arm Description
Participants in this group will be prescribed morning aerobic exercise.
Arm Title
PM-EX
Arm Type
Experimental
Arm Description
Participants in this group will be prescribed evening aerobic exercise.
Intervention Type
Behavioral
Intervention Name(s)
AM-EX
Intervention Description
AM will be instructed to perform 2000 kcal/wk of moderate to vigorous intensity aerobic exercise between the hours of 6 and 10 AM.
Intervention Type
Behavioral
Intervention Name(s)
PM-EX
Intervention Description
PM will be instructed to perform 2000 kcal/wk of moderate to vigorous intensity aerobic exercise between the hours of 3 and 7 PM.
Primary Outcome Measure Information:
Title
Feasibility of Recruitment (Number of contacts)
Description
Feasibility of recruitment will be evaluated by the number of people who contact study staff expressing interest in the study
Time Frame
End of enrollment (estimated between 6 and 12 months)
Title
Feasibility of Recruitment (eligibility rate)
Description
Feasibility of recruitment will be evaluated by calculating the number of volunteers who contact study staff to express interest in participation, the eligibility rate (number eligible divided by total volunteers)
Time Frame
End of enrollment (estimated between 6 and 12 months)
Title
Feasibility of Recruitment (enrollment rate)
Description
Feasibility of recruitment will be evaluated by calculating the enrollment rate (number enrolled divided by the number of total volunteers)
Time Frame
End of enrollment (estimated between 6 and 12 months)
Title
Adherence to Exercise Intervention (session attendance)
Description
Adherence will be calculated as (number of sessions attended/number of sessions prescribed)
Time Frame
Baseline to 15 weeks (reported at Week 15)
Title
Adherence to Exercise Intervention (kcal adherence)
Description
Adherence will be calculated as (number of kcals prescribed/ number of kcals of exercise completed)
Time Frame
Baseline to 15 weeks (reported at Week 15)
Secondary Outcome Measure Information:
Title
Weight Change (kg)
Description
Body weight will be measured at baseline and weeks 4, 8, 12, and 15 using a digital scale accurate to ±0.1 kg
Time Frame
Baseline to 15 weeks
Title
Physical Activity Change (min/d)
Description
Physical activity will be measured using the ActivPAL v4
Time Frame
Baseline to 15 weeks
Title
Meal Timing Change (clock time of first meal)
Description
Meal timing will be assessed using digital photography paired with a date and time stamp (time of first meal)
Time Frame
Baseline to 15 weeks
Title
Meal Timing Change (clock time of last meal)
Description
Meal timing will be assessed using digital photography paired with a date and time stamp (time of last meal)
Time Frame
Baseline to 15 weeks
Title
Sleep Timing Change (mid-point of sleep)
Description
Mid-point of sleep will be measured using the Actiwatch 2 (starting sleep time + (sleep duration/2))
Time Frame
Baseline to 15 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
56 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Female or Male
Age 18-55 years
Body Mass Index 25-40 kg/m2
Physically inactive: defined as self-reporting <150 minutes per week of physical activity at moderate intensity or greater on a regular basis over the past 3 months.
No self-report of acute or chronic disease (cardiovascular disease (CVD), diabetes, gastrointestinal disorders and orthopedic problems in particular)
No plans to relocate within the next 6 months
No plans for extended travel (> 1weeks) within the next 6 months
No nicotine use
Live or work within 30 minutes of the AHWC (exceptions may be made at the discretion of the Study PI on a case by case basis for highly motivated subjects).
Capable and willing to give informed consent, understand exclusion criteria, accept the randomized group assignment, and complete outcome measures.
Own a smartphone and willing to download and use text messaging for meal intake and other related assessments.
Have a primary care physician (or are willing to establish care with a primary care physician prior to study enrollment) to address medical issues which may arise during screening or study procedures/interventions.
For Females
Not currently pregnant or lactating
Not pregnant within the past 6 months
Not planning to become pregnant in the next 6 months; sexually active women of childbearing potential may be enrolled if they have had a tubal ligation or use a reliable means of contraception
Exclusion Criteria:
Diastolic blood pressure > 100 mm HG or systolic blood pressure > 160 mm HG.
Resting heart rate >100
Diabetes (fasting glucose ≥126 mg/dL or Hemoglobin A1C ≥6.5%)
Undiagnosed hypo- or hyper-thyroidism (TSH outside of the normal range) or history of uncontrolled thyroid disorder. History of thyroid disease or current thyroid disease treated with a stable medication regimen for at least 6 months is acceptable.
Hematocrit, white blood cell count or platelets significantly outside the normal reference range.
Triglycerides > 400 mg/dL
LDL cholesterol >200 mg/dL
Abnormal resting electrocardiogram (ECG): serious arrhythmias, including multifocal PVC's, frequent PVC's (defined as 10 or more per min), ventricular tachycardia (defined as runs of 3 or more successive PVC's), or sustained atrial tachyarrhythmia; 2nd or 3rd degree A-V block, QTc interval > 480 msec or other significant conduction defects.
Presence or history of any metabolic or chronic health problems which would affect appetite, food intake, energy metabolism, or ability to optimally participate in the exercise component including: CVD, peripheral vascular disease, cerebrovascular disease, significant cardiac arrhythmias or cardiac valve disease, diabetes, uncontrolled hyper- or hypothyroidism, uncontrolled hypertension, cancer (within the last 5 years, except skin cancer or other cancers considered cured with excellent prognosis), HIV infection, significant gastrointestinal disorders (described below), significant pulmonary disorders (described below), significant renal, musculoskeletal, neurologic, hematologic, or psychiatric disease.
Significant gastrointestinal disorders including: chronic malabsorptive conditions, peptic ulcer disease, Crohn's disease, Ulcerative Colitis, chronic diarrhea, or active gallbladder disease.
Significant pulmonary disorders including: chronic obstructive pulmonary disease (COPD), interstitial lung disease, cystic fibrosis, or uncontrolled asthma.
Symptoms suggestive of CVD: chest pain, shortness of breath at rest or with mild exertion, syncope.
Regular use of prescription or over-the-counter medications known to significantly impact appetite, weight, sleep, or energy metabolism (e.g. appetite suppressants, lithium, stimulants, anti-psychotics, tricyclic antidepressants)
Regular use of systemic steroids (other than Oral Contraceptive Pills).
Regular use of obesity pharmacotherapeutic agents within the last 6 months.
Previous obesity treatment with surgery or weight loss device, except: (1) liposuction and/or abdominoplasty if performed > 1 year before screening, (2) lap banding if the band has been removed > 1 year before screening, (3) intragastric balloon if the balloon has been removed > 1 year before screening (4) duodenal-jejunal bypass sleeve, if the sleeve has been removed > 1 year before screening or 5) AspireAssist or other endoscopically placed weight loss device if the device has been removed > 1 year before screening.
Current alcohol or substance abuse
Irregular sleep/wake patterns that may hinder ability to consistently exercise at a certain time of day (e.g. night shift-work, swing shifts, etc)
Currently dieting or planning to alter diet during the exercise intervention
Nicotine use (past 6 months)
History of clinically diagnosed eating disorders including anorexia nervosa, bulimia, binge eating disorder. Pattern of response on the QEWP-5 suggestive of possible binge eating disorder or bulimia will require further assessment by the Study MD to determine if it is appropriate for the subject to participate in the study.
Current severe depression or history of severe depression within the previous year, based on DSM-IV-TR criteria for Major Depressive Episode. Score > 18 on BDI will require further assessment by the Study MD to determine if it is appropriate for the subject to participate in the study.
History of other significant psychiatric illness (e.g. psychosis, schizophrenia, mania, bipolar disorder) which in the opinion of the Study MD would interfere with ability to adhere to dietary or exercise interventions.
Currently participating in or planning to participate in any formal weight loss or physical activity programs or clinical trials.
Weight loss >5% in past 3 months for any reason except post-partum weight loss, weight gain >% in past 3 months requires assessment by PI to determine reason for weight gain and if it is appropriate for the subject to participate in the study.
Weight loss of >50 lbs in past 3 years for any reason except post-partum weight loss.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Seth A Creasy, PhD
Organizational Affiliation
University of Colorado - Anschutz Medical Campus
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Colorado Anschutz Medical Campus
City
Aurora
State/Province
Colorado
ZIP/Postal Code
80045
Country
United States
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Morning Versus Evening Exercise for Adults With Overweight and Obesity
We'll reach out to this number within 24 hrs